[PTLA] Portola Pharmaceuticals, Inc.
Overview
Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization:
Exchange: NASDAQ
The data is delayed by 15 minutes.
Strongest Trends Summary For PTLA
PTLA is in the long-term down -65% below S&P in 3 years.
Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max
Chart type: absolute | relative to S&P
Description: Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops product candidates in the fields of thrombosis and hematology. Its lead compound, Betrixaban, is an oral, once-daily Factor Xa inhibitor in Phase III study for hospital to home prophylaxis of venous thromboembolism (VTE) in acute medically ill patients. The company?s lead development candidate, Andexanet Alfa, is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. Andexanet Alfa focuses on entering into Phase III registration studies. It has clinical collaboration agreements with various manufacturers of direct Factor Xa inhibitors, including Bristol-Myers Squibb Company, Pfizer Inc., Bayer Pharma, AG, Janssen Pharmaceuticals, Inc., and Daiichi Sankyo, Inc. The company is also developing Cerdulatinib, which is in Phase I/II proof-of-concept study, an orally available kinase inhibitor that inhibits spleen t
See how to gain 20% in 14 sec with TrendsInvesting
Fundamental Ratios
| Shares Outstanding | EPS | EPS Growth - 4 Quarters | EPS Growth - Q/Q | ||||
| EPS Growth - Y/Y | Sales Growth - 4 Quarters | -2.28% | Sales Growth - Q/Q | -2.2% | P/E | ||
| P/E To EPS Growth | P/S | P/BV | Price/Cash Per Share | ||||
| Price/Free Cash Flow | ROA | -31.53% | ROE | -36.59% | ROI | ||
| Current Ratio | 9.89 | Quick Ratio | Long Term Debt/Equity | Debt Ratio | 0.1 | ||
| Gross Margin | Operating Margin | -1592.24% | Net Profit Margin | -1595.01% | Dividend Payout Ratio | ||
| Dividend Yield |
Fundamental Data
| Cash From Financing Activities | 113.04 M | Cash From Investing Activities | 9.44 M | Cash From Operating Activities | -47.15 M | Gross Profit | |
| Net Profit | -46.91 M | Operating Profit | -46.5 M | Total Assets | 486.3 M | Total Current Assets | 403.45 M |
| Total Current Liabilities | 40.79 M | Total Debt | Total Liabilities | 67.32 M | Total Revenue | 2.36 M |
Technical Data
| High 52 week | 37.76 | Low 52 week | 15.46 | Last close | 30.94 | Last change | 1.91% |
| RSI | 68.73 | Average true range | 1.39 | Beta | 1.71 | Volume | 8.33 M |
| Simple moving average 20 days | 15.82% | Simple moving average 50 days | 15.78% | Simple moving average 200 days | 14.08% |
Performance Data
| Performance Week | 24.76% | Performance Month | 18.27% | Performance Quart | -2.7% | Performance Half | 8.41% |
| Performance Year | -17.97% | Performance Year-to-date | 58.5% | Volatility daily | 3.23% | Volatility weekly | 7.23% |
| Volatility monthly | 14.81% | Volatility yearly | 51.32% | Relative Volume | 1513.75% | Average Volume | 1.04 M |
| New High | New Low |
News
2020-01-17 13:25:08 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Portola Pharmaceuticals Inc. - PTLA
2020-01-17 12:04:00 | PORTOLA ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Portola Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
2020-01-17 12:00:00 | INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Portola Pharmaceuticals, Inc. Investors
2020-01-17 10:22:13 | Portola Pharmaceuticals Shareholder Alert - Kehoe Law Firm, P.C. Investigating Securities Claims on Behalf of Investors of Portola Pharmaceuticals – Class Action Filed Against PTLA
2020-01-17 09:07:00 | EQUITY ALERT: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Portola Pharmaceuticals, Inc. – PTLA
2020-01-16 22:07:00 | Glancy Prongay & Murray LLP Files First Securities Class Action on Behalf of Portola Pharmaceuticals, Inc. Investors
2020-01-14 16:03:00 | INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Portola Pharmaceuticals, Inc. and Encourages Investors With Losses to Contact the Firm
2020-01-10 18:41:00 | The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Portola Pharmaceuticals, Inc., PTLA
2020-01-10 17:24:00 | Lost Money in Portola Pharmaceuticals, Inc.?
2020-01-10 16:15:00 | PTLA LOSSES ALERT: Bernstein Liebhard LLP Announces an Investigation into Portola Pharmaceuticals Inc., and Encourages Investors with Losses to Contact the Firm
2020-01-10 15:30:00 | Glancy Prongay & Murray LLP Announces Investigation on Behalf of Portola Pharmaceuticals, Inc. Investors
2020-01-10 15:19:58 | Portola Pharmaceuticals Slump Ignites Heavy Call Trading
2020-01-10 13:57:00 | INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Portola Pharmaceuticals, Inc. Investors
2020-01-10 12:03:00 | PTLA Alert: Johnson Fistel Launches Investigation into Portola Pharmaceuticals; Investors Encouraged to Contact Firm
2020-01-10 10:01:00 | Portola's stock falls on weak Andexxa sales
2020-01-10 07:13:12 | The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx
2020-01-09 16:01:00 | Portola Announces Preliminary Full Year 2019 Andexxa Global Net Revenues of Approximately $111 Million
2019-12-23 08:30:00 | Portola Pharmaceuticals to Webcast Corporate Update on January 14, 2020
2019-12-17 08:30:00 | Portola Pharmaceuticals to Support New American Heart Association Initiative to Address Hemorrhagic Stroke
2019-12-10 12:06:10 | Why health care innovation is where investors should look
2019-12-09 15:21:00 | Portola Pharmaceuticals Presents New Interim Data at the 61st ASH Meeting on its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated Patients with Relapsed/Refractory Follicular Lymphoma
2019-12-09 09:52:46 | Should You Buy Portola Pharmaceuticals Inc PTLA?
2019-12-08 12:00:00 | Portola Pharmaceuticals Presents New Interim Data from Ongoing Phase 2a Study of its Oral SYK/JAK Inhibitor Cerdulatinib in Heavily Pre-Treated T-Cell Malignancies
2019-12-07 08:35:07 | The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
2019-11-15 16:25:00 | Andexxa Highlighted as a First-Line Factor Xa Reversal Option by the American College of Emergency Physicians
2019-11-08 11:31:04 | Pacira's PCRX Q3 Earnings Top Estimates, Revenues Rise Y/Y
2019-11-07 09:22:11 | Portola Pharmaceuticals, Inc. NASDAQ:PTLA: Is Breakeven Near?
2019-11-06 11:35:26 | Edited Transcript of PTLA earnings conference call or presentation 5-Nov-19 9:30pm GMT
2019-11-06 10:41:03 | Mallinckrodt MNK Q3 Earnings Beat, Stock Down on Sales Miss
2019-11-06 10:07:00 | Portola Pharmaceuticals to Present Multiple Abstracts at the 61st American Society of Hematology ASH Annual Meeting
2019-11-05 18:05:11 | Portola Pharmaceuticals PTLA Reports Q3 Loss, Tops Revenue Estimates
2019-11-05 16:00:00 | Portola Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
2019-11-05 11:17:04 | Bausch BHC Beats on Q3 Earnings & Sales, Raises Guidance
2019-11-05 10:42:03 | Endo ENDP Q3 Earnings & Revenues Beat Estimates, Down Y/Y
2019-11-01 16:30:00 | Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635c4
2019-11-01 11:07:03 | WIll Allergan AGN Beat Estimates This Earnings Season?
2019-10-30 12:01:04 | Guardant Health GH to Report Q3 Earnings: What's in Store?
2019-10-29 10:33:02 | Portola Pharmaceuticals PTLA Expected to Beat Earnings Estimates: Can the Stock Move Higher?
2019-10-29 09:46:01 | Catalyst Pharma CPRX to Post Q3 Earnings: What's in Store?
2019-10-28 09:59:23 | Portola Pharmaceuticals Inc PTLA: Are Hedge Funds Right About This Stock?
2019-10-28 09:38:01 | Sony SNE to Report Q2 Earnings: What's in the Offing?
2019-10-28 09:00:00 | Portola Pharmaceuticals Presents New Analysis from the ANNEXA-4 Study of its Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Acute Gastrointestinal Bleeding
2019-10-18 10:23:24 | These 24 Bay Area drug and diagnostics companies quietly raised nearly $3B this year
2019-10-15 08:30:00 | Portola Pharmaceuticals to Announce Third Quarter 2019 Financial Results on Tuesday, November 5, 2019
2019-09-19 08:20:00 | Portola Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors
2019-08-22 08:30:00 | Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences
2019-08-16 11:08:39 | Here's Why Portola Pharmaceuticals NASDAQ:PTLA Can Afford Some Debt
2019-08-13 19:32:00 | Portola Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2019-08-13 07:25:15 | The Daily Biotech Pulse: Jazz Goes Shopping, Portola Offering, Novelion Delays Quarterly Results
2019-08-12 16:43:00 | Portola Pharmaceuticals Announces Proposed Offering of Common Stock